Arcoma (ARCOMA) Q3 2026 earnings summary

Executive summary

• Q3 revenue was SEK 26.2m, down from SEK 29.9m YoY, while EBITDA rose to SEK 4.1m from SEK 3.9m; EBITDA margin improved to 16% from 13%.

• North America grew 11% YoY and was the strongest market; European sales fell 25% amid uneven investment activity and longer customer decision cycles.

Financial highlights

• Q3 gross margin was 45.7%, up from 41.3% YoY; EBIT was SEK 2.9m versus SEK 2.0m, and net income was SEK 2.4m versus SEK 1.6m.

• Q3 profit before tax was SEK 3.0m versus SEK 2.0m; EPS was SEK 0.16 versus SEK 0.11.

• 9M revenue was SEK 89.0m versus SEK 96.1m; EBITDA was SEK 7.9m versus SEK 10.2m, net income SEK 3.5m versus SEK 3.6m, and EPS SEK 0.24 versus SEK 0.25.

Outlook and guidance

• Entering Q4 with a balanced market view; focus remains on strengthening sales across priority markets, with long-term demand drivers in diagnostic imaging described as strong.

• New camera-based workflow features are in development and expected to launch in Q4; continued product-development investment and partner activity are intended to support future growth.